SIRT3 Expression Predicts Overall Survival and Neoadjuvant Chemosensitivity in Triple-Negative Breast Cancer.

Published in: Cancer management and research (2024)

Our study suggests that SIRT3 is a potential biomarker for both OS and neoadjuvant chemosensitivity in TNBC. It may also assist in selecting suitable candidates and treatment options for TNBC patients.

Keyphrases

rectal cancer
end stage renal disease
lymph node
locally advanced
ejection fraction
chronic kidney disease
poor prognosis
newly diagnosed
oxidative stress
prognostic factors
ischemia reperfusion injury
peritoneal dialysis
squamous cell carcinoma
radiation therapy
binding protein